
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health has demonstrated strong market leadership through its flagship product, Simparica Trio, which holds over 50% market share, while its product Credelio Quattro is projected to improve its market position to 16.8% by 2026, signaling robust growth potential. Additionally, notable year-over-year growth for other product lines, such as the Advantage Family and Seresto, at +33% and +28% respectively for the third quarter of 2025, indicates a solid upward trend in performance. These factors collectively contribute to a favorable outlook for Elanco's stock as the company continues to expand its presence and market share in the animal health sector.
Bears say
Elanco Animal Health's financial outlook appears negative due to concerns regarding its refinancing risks, as highlighted by Dentsply Sirona's recent high-interest offering, which could impact earnings growth in 2026. Despite a significant revenue increase of approximately 50%, the company's EBITDA margin has declined by a few hundred basis points, indicating potential challenges in cost management and profitability. Furthermore, while there was a reported EBITDA outperformance of $28 million in Q2, this may not be sufficient to mitigate ongoing concerns about future earnings and overall financial health.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares